Anpheros Search · Treatment

Vericiguat

Also known as: Verquvo

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, Vericiguat is indicated for the treatment of symptomatic chronic heart failure. In the United States, this soluble guanylate cyclase stimulator is indicated to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or the need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and an ejection fraction less than 45%. Vericiguat is listed by the cited source as having an approved use for the condition of heart failure.

From: Source: European Medicines Agency (EMA), Verquvo — EPAR, 21/04/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
2475830 vericiguat
EMA
EMEA/H/C/005319

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Verquvo

Treatment of symptomatic chronic heart failure

Source: European Medicines Agency (EMA), Verquvo — EPAR, 21/04/2026. © European Medicines Agency.

Document date: 21/04/2026 · Official document →

FDA (USA) VERQUVO

1 INDICATIONS AND USAGE VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] . VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. ( 1 )

Data provided by the U.S. Food and Drug Administration.

Document date: 20260121 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Vericiguat approved for in the European Union?

Treatment of symptomatic chronic heart failure (Source: European Medicines Agency (EMA), Verquvo — EPAR, 21/04/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • Data provided by the U.S. Food and Drug Administration.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Verquvo — EPAR, 21/04/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →